Ibogaine Therapy: Forms and Dose Regimens Howard S. Lotsof, B.F.A., C.M.A. President Dora Weiner Foundation Staten Island, NY

Slides:



Advertisements
Similar presentations
Patient Medication Acceptability and Treatment Options: Ibogaine Methadone Buprenorphine Howard S. Lotsof DORA WEINER FOUNDATION.
Advertisements

AbstractSchema Conclusion Pharmacokinetic profile of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous.
Ibogaine Dr.Moshe Zer-Zion Beer-Yaacov Mental Health Center Israel.
Significance of “Unofficial” Ibogaine Treatment Scenes The existence of these scenes indicates demand for alternatives to existing treatment options. Averse.
Ibogaine Community Worldwide User-to-User BrugerForeningen International Drug Users Day (IDUD) 2008 Copenhagen, Denmark 31 October - 3 November 2008 Howard.
Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.
1. Ibogaine (brief review) 2. Ibogaine Development Introduction to Presentation by HS Lotsof 2006 NYC Ibogaine Conference Columbia University Saturday,
Pharmacology Introduction
Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY Invitational.
The European Network for Traumatic Stress Training & Practice
Iboga & Ibogaine: From the forest to the laboratory Howard S. Lotsof Dora Weiner Foundation Staten Island, NY Les Journees Gabonaises aux USA Tacoma, MD.
Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY International.
That is the problem!!!!  Acute colonic pseudo-obstruction (ACPO) is characterised by massive colonic dilation with symptoms and signs of colonic obstruction.
Understanding the Concept of Equivalence and Non-Inferiority Trials CM Gibson, 2000.
A History of the Science, Politics and Advocacy of ibogaine: A Brief Overview Howard S. Lotsof Dora Weiner Foundation Staten Island, NY IHRA 19th International.
Safety and effect of an extract from Ganoderma lucidum (Reishi) on NK cell numbers in HIV+ individuals not taking antiretroviral therapy. JT Leonard 1,
Exploring Ibogaine’s Potential in the Treatment of Addiction Multidisciplinary Association for Psychedelic Studies (MAPS) Presented.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Unit 1 Test Review Write the numbers 1 to 14 on a blank piece of paper.
Policy #: H:  To provide guidelines for the instruction of patients and family/caregivers regarding the safe, effective use of medication  To.
INTRODUCTION Many studies conducted in 1950’s and 1960’s suggest that hallucinogen assisted psychedelic psychotherapy may offer an effective treatment.
Stats Review. Identify the appropriate statistic A researcher randomly assigns five individuals to receive a new experimental procedure and five to a.
Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons Valerie Mojeiko Multidisciplinary Association for Psychedelic.
 Create a safe place for people to express themselves and try new ways of interacting  Learn fluid boundary interactions and boundary choices  Connecting.
A History of the Science and Politics of ibogaine Howard S. Lotsof Dora Weiner Foundation Staten Island, 6th National HRC Conference Oakland, CA November.
Multiple dosing: intravenous bolus administration
Ibogaine: To Have or Have Not Howard S. Lotsof Dora Weiner Foundation
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Methadone and Ibogaine A Historical Comparison of Patient Status and Advocacy Issues Howard S. Lotsof.
INTRODUCTION CLINICAL PHARMACOKINETICS
General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.
Event and Peri-procedural Replacement Therapy in Patients with Hemophilia.
Objectives When administering buprenorphine/naloxone in a MAP program, what are the Differences from administering other medications? Similarities.
Substance Abuse James May PH.D. Director SAS Richmond Behavioral Health Authority 2011.
Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY 6th National.
C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
Learning objectives To know what data is available from pharmacokinetic studies in man and how to handle it To know how to calculate the basic pharmacokinetic.
Foundations of Art. What is it and why do we need to use it in art? VALUE- refers to the lightness or darkness of a color. It is needed to express volume.
Sublingual Allergy Treatment. Sublingual Immunotherapy Immunotherapy is widely used by allergy specialists because it treats the underlying cause of allergic.
Best Ibogaine treatment centers Welcome to holistic sanctuary drug rehab center in Mexico. We are the best ibogaine treatment center and provide good service.
Acupuncture as an Effective Method for Pain Management in Post-Op Care
Examining Potential Misuse of Gabapentin Among Patients Admitted to an Inpatient Behavioral Health Unit Samuel Kubas a, Pharm.D. Candidate 2018; Lucas.
From: Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled TreatmentA Randomized Trial Ann Intern Med.
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Presentation On Routes of drug administration & it’s significance
Population (millions)
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
TREATMENT ARM B: Cycles 1–3: Cycles 4+: 5-FU continuous infusion
Dose-response relationships. A
Dose-escalation patient response.
Pain Physicians NY (Brooklyn & NYC) provides a full range of advanced pain management services to help the patients return to a healthy and pain-free life style.
CONCLUSIONS AND DISCUSSION
5 Pharmacodynamics.
Dose-finding designs incorporating toxicity data from multiple treatment cycles and continuous efficacy outcome Sumithra J. Mandrekar Mayo Clinic Invited.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.
Krop I et al. SABCS 2009;Abstract 5090.
Pain Management: Patients Maintained on Buprenorphine
Diabetes hazard rates by number of visits with reported statin use.
Specific Therapy The American Heart Association recently published new guidelines for the management of IE, including specific treatment recommendations.
1 Concentration-time curve
“Say hello to my little neuropeptide”
Figure 2 Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical.
Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study  Kim Fisher, PhD, Carla Stiles,
SQUARE ROOT Functions 4/6/2019 4:09 PM 8-7: Square Root Graphs.
Current Evaluation Process
Classification and Treatment Plans
Massachusetts Consultation Service for the Treatment of Addiction and Pain (MCSTAP) Offers real-time phone consultation to primary care practices on safe.
Presentation transcript:

Ibogaine Therapy: Forms and Dose Regimens Howard S. Lotsof, B.F.A., C.M.A. President Dora Weiner Foundation Staten Island, NY

Forms in Current Use Botanical - root bark Total alkaloid extract purified ibogaine

Tabernanthe iboga shrub

Roots contain ibogaine

Total Alkaloid Extract Large piece 2cm x 2cm, approx 4 grams Estimate 15% ibogaine Courtesy Sara Glatt

Ibogaine HCl 99.4% purity

All forms have multiple treatment applications 1.Chemical use disorders 2.Pain management 3.Psychotherapy 4.Initiatory sessions

Each form has 1.Different onset 2.Different duration of action 3.And significant diversity across the patient population

Dose and Dose Regimen 1.Single dose 2.Multiple 1.Escalating 2.Deescalating 3.Linear

All doses are representative. Doses, including single administration doses are determined on a patient by patient basis. The graphs of dose regimens and information that follow should not be used by persons without experience to self- administer or administer to others any dose of ibogaine or total alkaloid extract of Tabernanthe iboga.

Single dose regimens usually fall between 10mg/kg and 22mg/kg depending on type of therapy offered: opioid dependence, stimulant dependence, psychospiritual, etc. Most doses fall in the 15mg/kg - 20mg/kg dose range to reach full therapeutic effects.

All doses and dose regimens shown or discussed are representative and are not indicated to be provided to any other patient or subject. All doses and dose regimens are made on a patient by patient basis upon knowledge and prior art.